Abbvie Inc (ABBV) Stock Price, Quote & News

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 847 932 7900

Website: www.abbvie.com

Address:

1 North Waukegan Road, North Chicago, United States

Maxwell_Osgood Jul. 28 at 11:13 PM

$ABBV Good one!

0 · Reply

MadisonRamsey Jul. 28 at 10:12 PM

$IMMX $IBB $SPCH $JEPQ $ABBV ¢¢¢

1 · Reply

SenefAS Jul. 28 at 8:10 PM

When I post this tweet Genmab was at 25$ now closing at 29$ and average target it’s 37.96$ it’s still not late to be in… Earnings are in 8 days… Tic tac $GMAB $GMAB.CO $ABBV $JNJ

0 · Reply

55X_ROI_Q1_2026 Jul. 28 at 8:08 PM

$SLS Lowlife POS --- why can't any of your short scumbag friends find 1 trial -- just 1 for BAT - that casts doubt on Gps success... BAT was APPROVED in 2018 - and you can't find 1 trial??? - all you lowlife lying about a company working on cancer cures Deserves to Catch a Case of the big C yourselves, or maybe someone you love... would be deserving Karmic justice. $XBI $ABBV

2 · Reply

55X_ROI_Q1_2026 Jul. 28 at 6:31 PM

$SLS SLS will be Bought for close to $40B -- will Still allow plenty of Upside for $LLY / $ABBV * Gps Phase 2 MOS for CR1 - First Remission Patients Absent transplant was not yet reached and > 67.6 Months. Dr. K and the MDACC team published Benchmark CR1 MOS of 19 months. Gps > 67.6 VS BAT 19 --- It is NOT COMPLICATED This is a look at the CR1 Market Opportunity: 40,000 Patients a Year in the US/Eu/Japan $300K rev per Patient year 1 / 5 Year Anticipated Dosing.

1 · Reply

55X_ROI_Q1_2026 Jul. 28 at 5:51 PM

$SLS $ABBV Do all the SHORT Lowlife Liars Know - BAT - Aza/VEN FAILED the VIALE-M - Phase 3 Maintenance Trial for CR1 Patients who are Ineligible for Transplant? Yes // You - You dumb as F tool -- do you not get it?

0 · Reply

55X_ROI_Q1_2026 Jul. 28 at 4:23 PM

$SLS Look at this SHORT IDIOT TOOL - Stuck its MEAT into the GRINDER... Dr. Tsirigotis KNOWS --- He absolutely Knows -- treats more REGAL P3 Patients than any other clinician and Stated on the Record - "MOS for patients on BAT is extremely poor, just 5 -7 months" and " I STRONGLY Believe Gps will Reach the Primary Endpoint..." So Many Idiot short tools / retail traders too, getting FLEECED... $ABBV $A

1 · Reply

55X_ROI_Q1_2026 Jul. 28 at 4:19 PM

$SLS This is only for the DumbAsF Retail SHORTS --- $ABBV Conducted 3 Large Phase 3 Trials with Aza+VEN that FAILED - the BAT for the SLS Control ARM... FAILED 3 Large AML REMISSION MAINTENANCE TRIALS VIALE-T - Post Transplant Remission Maintenance Trial - FAILED VIALE-M - M for Maintenance -FAILED a CR1 Remission Maintenance Trial ... you dumb as F broke D tools stuck your meat into the Grinder. ahaha... $XBI market offering Major Discounts for the Investment Opportunity of a Lifetime.

0 · Reply

55X_ROI_Q1_2026 Jul. 28 at 4:04 PM

$SLS Overall Median Survival of 19 months for AML Patients in First Remission (CR1) on BAT - absent Transplant. Gps Phase 2 MOS for CR2 Patients was 21 months Statistically Significant - Longer - and in an Older (74), ALL MRD+ Patient Set - who Got Less GPS Immunotherapy than the P3 GPS patients have Gotten - just a max of 12 doses in Y1 only, vs 15 in the P3 w indefinite dosing for as long as they remain in remission. - the Patients Not able to Withstand Intensive Treatment - Chemo 7+3 - those Patients on VEN+Aza/Deci or LIT have even worse survival --- Universally understood that a Second Remission Duration is about Half the First ... $ABBV WILL BUY SLS

0 · Reply

Layne_Thomas_Staley Jul. 28 at 3:42 PM

$GANX $ABBV Bought MTK458 back in 2023 🤔

1 · Reply

Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

ABBV GMAB

Jul 17, 2026, 8:00 AM EDT - 11 days ago

Market Cap	458.24B
Revenue (ttm)	61.16B
Net Income (ttm)	4.23B
EPS (ttm)	N/A
PE Ratio	25.21
Forward PE	18.12
Profit Margin	6.91%
Debt to Equity Ratio	-11.02

Volume	7,060,443
Avg Vol	6,973,762
Day's Range	N/A - N/A
Shares Out	1.77B
Stochastic %K	73%
Beta	0.30
Analysts	Strong Sell
Price Target	$264.93